CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
Trial details
- Registry ID
- NCT06699836
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as PRO 140
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched RegimenNCT06699836 | CytoDyn, Inc. | Phase 2 | Active not recruiting | 2028-01Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |